Biotech firm Vaxart, Inc. is dedicated to developing and discovering oral recombinant protein vaccines using its proprietary technology. One of the company's current products in the pipeline is an oral tablet vaccine for norovirus, which is undergoing Phase II clinical trials alongside a bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains. Vaxart is also developing a seasonal influenza vaccine, currently in Phase II clinical trials focused on treating H1 influenza infections. In addition, the company's preclinical work is focused on a respiratory syncytial virus vaccine using its novel oral platform. Vaxart's cutting-edge technology is also in the midst of Phase II clinical trials for a coronavirus vaccine created to treat SARS-CoV-2 infections. Finally, Vaxart is working on a human papillomavirus therapeutic vaccine targeting HPV 16 and HPV 18 to treat cervical cancers and precancerous cervical dysplasia. The company also boasts a license agreement with Altesa Biosciences, Inc. to develop and commercialize the capsid-binding broad spectrum antiviral Vapendavir. With headquarters located in South San Francisco, California, Vaxart is a promising biotech company to watch in the coming years.
Vaxart's ticker is VXRT
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 11-50 employees working at Vaxart
It is vaxart.com
Vaxart is in the Healthcare sector
Vaxart is in the Biotechnology industry
The following five companies are Vaxart's industry peers: